Roth Capital Has Negative View of Globus Medical Q1 Earnings

Globus Medical, Inc. (NYSE:GMED - Free Report) - Investment analysts at Roth Capital cut their Q1 2025 earnings per share (EPS) estimates for Globus Medical in a report issued on Monday, December 16th. Roth Capital analyst J. Wittes now forecasts that the medical device company will post earnings per share of $0.75 for the quarter, down from their prior forecast of $0.80. The consensus estimate for Globus Medical's current full-year earnings is $2.97 per share. Roth Capital also issued estimates for Globus Medical's Q2 2025 earnings at $0.84 EPS, Q3 2025 earnings at $0.88 EPS, FY2025 earnings at $3.44 EPS, FY2026 earnings at $4.30 EPS and FY2027 earnings at $4.76 EPS.

Globus Medical (NYSE:GMED - Get Free Report) last posted its earnings results on Tuesday, November 5th. The medical device company reported $0.83 earnings per share for the quarter, beating analysts' consensus estimates of $0.65 by $0.18. The business had revenue of $625.71 million for the quarter, compared to analysts' expectations of $604.69 million. Globus Medical had a net margin of 3.69% and a return on equity of 9.98%. The firm's revenue for the quarter was up 63.1% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.57 earnings per share.

GMED has been the subject of several other reports. Bank of America lifted their price target on shares of Globus Medical from $55.00 to $80.00 and gave the company an "underperform" rating in a report on Wednesday, November 6th. Royal Bank of Canada boosted their target price on Globus Medical from $80.00 to $92.00 and gave the stock an "outperform" rating in a report on Wednesday, November 6th. Needham & Company LLC reaffirmed a "hold" rating on shares of Globus Medical in a report on Wednesday, November 6th. Stifel Nicolaus boosted their price objective on Globus Medical from $80.00 to $92.00 and gave the stock a "buy" rating in a research note on Wednesday, November 6th. Finally, Canaccord Genuity Group raised their target price on Globus Medical from $85.00 to $92.00 and gave the company a "buy" rating in a research note on Monday, December 9th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and nine have given a buy rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $94.55.

Globus Medical Stock Performance

Shares of NYSE:GMED traded down $1.64 on Wednesday, hitting $81.78. The stock had a trading volume of 1,347,038 shares, compared to its average volume of 995,014. The firm's 50 day moving average price is $79.31 and its 200-day moving average price is $73.10. Globus Medical has a twelve month low of $49.33 and a twelve month high of $87.22. The company has a market capitalization of $11.14 billion, a price-to-earnings ratio of 122.06, a price-to-earnings-growth ratio of 1.99 and a beta of 1.19.

Institutional Trading of Globus Medical

A number of large investors have recently bought and sold shares of the business. Coldstream Capital Management Inc. increased its position in shares of Globus Medical by 2.2% during the third quarter. Coldstream Capital Management Inc. now owns 6,219 shares of the medical device company's stock worth $447,000 after acquiring an additional 131 shares in the last quarter. Stephens Inc. AR boosted its stake in Globus Medical by 3.4% in the 3rd quarter. Stephens Inc. AR now owns 4,229 shares of the medical device company's stock worth $303,000 after purchasing an additional 138 shares during the period. Wealth Enhancement Advisory Services LLC increased its holdings in Globus Medical by 2.5% during the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 5,637 shares of the medical device company's stock worth $403,000 after purchasing an additional 140 shares in the last quarter. Nisa Investment Advisors LLC raised its stake in shares of Globus Medical by 15.9% in the 2nd quarter. Nisa Investment Advisors LLC now owns 1,165 shares of the medical device company's stock valued at $80,000 after purchasing an additional 160 shares during the period. Finally, Van ECK Associates Corp lifted its holdings in shares of Globus Medical by 0.4% in the second quarter. Van ECK Associates Corp now owns 45,922 shares of the medical device company's stock valued at $3,145,000 after purchasing an additional 183 shares in the last quarter. 95.16% of the stock is owned by institutional investors.

Insider Transactions at Globus Medical

In other Globus Medical news, SVP Kelly Huller sold 2,500 shares of the company's stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $87.00, for a total value of $217,500.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Daniel T. Scavilla sold 60,000 shares of Globus Medical stock in a transaction on Wednesday, November 6th. The stock was sold at an average price of $80.02, for a total transaction of $4,801,200.00. The disclosure for this sale can be found here. Insiders have sold 97,500 shares of company stock worth $7,674,950 in the last three months. Insiders own 18.54% of the company's stock.

About Globus Medical

Globus Medical, Inc, a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative and congenital conditions, deformity, tumors, and trauma injuries; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives.